Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667782 | 1.00 | ADRB3 (0.62) | ADRB3ADRB1ADRB2CYP1A2ALOX15 | |
| SCHEMBL667783 | 1.00 | ADRB3 (0.62) | ADRB3ADRB1ADRB2CYP1A2ALOX15 | |
| SCHEMBL667469 | 0.89 | ALOX15 (0.69) | ADRB3ADRB1ADRB2CYP1A2ALOX15 | |
| SCHEMBL667471 | 0.89 | ALOX15 (0.69) | ADRB3ADRB1ADRB2CYP1A2ALOX15 | |
| SCHEMBL667470 | 0.89 | ALOX15 (0.69) | ADRB3ADRB1ADRB2CYP1A2ALOX15 | |
| SCHEMBL6925856 | 0.89 | ADRB3 (0.65) | ADRB3ADRB1ADRB2ALOX15 | |
| SCHEMBL6925853 | 0.89 | ADRB3 (0.65) | ADRB3ADRB1ADRB2ALOX15 | |
| SCHEMBL6925849 | 0.89 | ADRB3 (0.65) | ADRB3ADRB1ADRB2ALOX15 | |
| Hydrochloric Acid SCHEMBL6136770 | 0.88 | ALOX15 (0.71) | ADRB3ADRB1ADRB2CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL6136778 | 0.88 | ALOX15 (0.71) | ADRB3ADRB1ADRB2CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099439-A2 | Use of apo B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099441-A2 | Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | claimed |
| US-5977124-A | β-adrenergic agonists | PFIZER INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0828712-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-03-18 | — | — | EP | claimed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | claimed |
| WO-1996035670-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | claimed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | disclosed |
| EP-0828712-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035670-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | ADRB3 59/4885ADRB1 49/4885ADRB2 77/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | ADRB3 59/4885ADRB1 49/4885ADRB2 77/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | ADRB3 59/4885ADRB1 49/4885ADRB2 77/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | ADRB3 2257/4885ADRB1 3245/4885ADRB2 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.